ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
118.856,48
-0,77%
S&P 500
5.827,04
-1,54%
US Dollar vs BRL
6,1621
0,62%
Bitcoin
93.837,79
-0,69%
Brent Oil
80,455
-0,20%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Oruka Therapeutics Inc (ORKA)

  7. Oruka Therapeutics Inc (ORKA) Notícias

ORKA

Oruka Therapeutics (ORKA)

Oruka Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ORKA
DataHoraFonteTítuloCódigoCompanhia
19/12/202409:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORKAOruka Therapeutics Inc
19/12/202409:00GlobeNewswire Inc.Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 AntibodyNASDAQ:ORKAOruka Therapeutics Inc
18/12/202409:00GlobeNewswire Inc.Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)NASDAQ:ORKAOruka Therapeutics Inc
27/11/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ORKAOruka Therapeutics Inc
21/11/202420:30Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:ORKAOruka Therapeutics Inc
21/11/202420:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORKAOruka Therapeutics Inc
19/11/202410:00GlobeNewswire Inc.Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare ConferenceNASDAQ:ORKAOruka Therapeutics Inc
14/11/202421:38Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ORKAOruka Therapeutics Inc
14/11/202419:20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ORKAOruka Therapeutics Inc
14/11/202408:37Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ORKAOruka Therapeutics Inc
13/11/202418:25GlobeNewswire Inc.Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ORKAOruka Therapeutics Inc
13/11/202418:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ORKAOruka Therapeutics Inc
04/11/202409:00GlobeNewswire Inc.Oruka Therapeutics to Present at Multiple November Investor ConferencesNASDAQ:ORKAOruka Therapeutics Inc
18/10/202417:11Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ORKAOruka Therapeutics Inc
25/09/202408:08GlobeNewswire Inc.Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology CongressNASDAQ:ORKAOruka Therapeutics Inc
12/09/202408:05GlobeNewswire Inc.Oruka Therapeutics Announces $200 Million Private PlacementNASDAQ:ORKAOruka Therapeutics Inc
12/09/202408:00GlobeNewswire Inc.Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19NASDAQ:ORKAOruka Therapeutics Inc
06/09/202418:08Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:ORKAOruka Therapeutics Inc
06/09/202418:07Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ORKAOruka Therapeutics Inc
03/09/202408:00GlobeNewswire Inc.Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 MillionNASDAQ:ORKAOruka Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ORKA

Seu Histórico Recente

BOV
HOOT4
HOTEIS OTHON PN
BOV
GPIV33
Gp Investments
BOV
IBOV
Índice Bovespa
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados